<DOC>
	<DOC>NCT00225121</DOC>
	<brief_summary>The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.</brief_summary>
	<brief_title>Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Malignant solid tumor for which there is no currently approved treatment Adequate bone marrow, liver, cardiac, and kidney function Cardiac disease Anticancer therapy within 46 weeks (depending on therapy) Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>